Reuters logo
BRIEF-Kiadis Pharma receives FDA regenerative medicine advanced therapy (RMAT) designation for ATIR101
September 20, 2017 / 5:10 AM / 3 months ago

BRIEF-Kiadis Pharma receives FDA regenerative medicine advanced therapy (RMAT) designation for ATIR101

Sept 20 (Reuters) - KIADIS PHARMA NV:

* KIADIS PHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ATIR101™

* ‍IN EUROPE ATIR101 WAS FILED FOR REGISTRATION IN APRIL 2017 AND WE CONTINUE TO PREPARE COMPANY FOR POTENTIAL EUROPEAN LAUNCH IN 2019 - CEO​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below